Ketamine and Magnesium in Erector Spinae Plane Block

Çukurova University

Status and phase: Completed; Phase 4

Conditions: Postoperative Analgesia

Treatments: Drug: Ketamine Hydrochloride; Drug: Bupivacain; Drug: Magnesium sulfate

Study type: Interventional

Funder types: Other

Identifiers

NCT05855798

esp01

Details and patient eligibility

About

In this study, it will aimed to evaluate the effect of magnesium sulfate and ketamine HCl added to local anesthetic on postoperative pain management in the ultrasound-guided erector spina plane (ESP) block in patients will undergo video-assisted thoracoscopic surgery.

Full description

Patients who will undergo lung resection with elective video-assisted thoracoscopic surgery will be included in the study. After routine monitoring, general anesthesia induction, and intubation with a double-lumen tube, patients who are placed in a lateral position will receive an ESP block at the T5 level, accompanied by ultrasonography, for postoperative analgesia.

For this purpose; Group I (control group) 0.5% bupivacaine 20 ml, Group II 0.5% bupivacaine 20 ml+150 mg MgSO4, Group III 0% ,5 bupivacaine 20 ml+2 mg/kg ketamine HCl will be administered. In all groups, the total volume will completed to 25 ml with 0.9% NaCl.

After surgery, hemodynamic values (heart rate, systolic and diastolic blood pressure), oxygen saturation, VAS scores (at rest and effort), Ramsey sedation score, patients satisfaction scores, PCA morphine consumption, additional analgesic requirements, and side effects will be recorded.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• lung resection with video-assisted thoracoscopy,
• voluntarily agree to participate in the study,
• over 18 years old,
• ASA I-III

Exclusion criteria

• ASA>III
• Coagulation disorders or anticoagulant agent therapy,
• Allergy or hypersensitivity to any drug to be will be used in the study,
• Epilepsy,
• High intracranial pressure,
• Unwillingness to participate in the study
• Inability to use the PCA device

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

60 participants in 3 patient groups

control group

Active Comparator group

Description:

Erector spinae plane block with 20 mL 0.5% bupivacaine

Treatment:

Drug: Bupivacain

magnesium group

Active Comparator group

Description:

Erector spinae plane block with 20 mL 0.5% bupivacaine+150 mg magnesium sulphate

Treatment:

Drug: Magnesium sulfate

Drug: Bupivacain

ketamine group

Active Comparator group

Description:

Erector spinae plane block with 20 mL 0.5% bupivacaine+2 mg/kg ketamine

Treatment:

Drug: Bupivacain

Drug: Ketamine Hydrochloride